<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>AMITIZA - lubiprostone capsule, gelatin coated </strong><br>STAT RX USA LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use AMITIZA safely and effectively. See full prescribing information for AMITIZA. <br> <br>AMITIZA (lubiprostone) capsule, gelatin coated for oral use <br>Initial U.S. Approval: 2006</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Amitiza is a chloride channel activator indicated for:  </p>
<ul>
<li>Treatment of chronic idiopathic <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> in adults <a href="#B417E142-21DE-4A69-B3F3-C3110156B6F7">(1.1)</a>
</li>
<li>Treatment of <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">irritable bowel syndrome</span> with <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> in women ≥ 18 years old <a href="#B417E142-21DE-4A69-B3F3-C3110156B6F2">(1.2)</a>
</li>
</ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta"><span class="Bold">Chronic idiopathic <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span></span> </p>
<ul><li>24 mcg taken twice daily orally with food and water <a href="#B417E142-21DE-4A69-B3F3-C3110156B6F3">(2.1)</a>
</li></ul>
<p class="Highlighta"><span class="Bold"><span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">Irritable bowel syndrome</span> with <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span></span> </p>
<ul><li>8 mcg taken twice daily orally with food and water <a href="#B417E142-21DE-4A69-B3F3-C3110156B6F4">(2.2)</a>
</li></ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul><li>Gelatin capsules: 8 mcg and 24 mcg <a href="#EB75313E-276E-4F49-AB3F-C919ED20A936">(3)</a>
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul><li>Patients with known or suspected mechanical <span class="product-label-link" type="condition" conceptid="4129389" conceptname="Gastrointestinal obstruction">gastrointestinal obstruction</span> should not receive Amitiza <a href="#C0725CD2-D44E-411A-B453-81F141BE2FC3">(4)</a>
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Women who could become pregnant should have a <span class="product-label-link" type="condition" conceptid="4094448" conceptname="Pregnancy test negative">negative pregnancy test</span> prior to beginning therapy and should be capable of complying with effective contraceptive measures <a href="#E8698946-AFB8-492B-A57E-06DB903FCBC5">(8.1)</a>
</li>
<li>Use during pregnancy only if the potential benefit justifies the potential risk to the fetus <a href="#B417E142-21DE-4A69-B3F3-C3110156B6F0">(5.1)</a>
</li>
<li>Patients may experience <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>; concomitant administration of food may reduce this symptom <a href="#DB8DEB82-2604-4B6F-81CB-F668F46A382F">(5.2)</a>
</li>
<li>Do not prescribe for patients that have severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> <a href="#D10AA7B0-552D-4F51-A02C-7E1437DE2B52">(5.3)</a>
</li>
<li>Patients taking Amitiza may experience <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> within an hour of first dose. This symptom generally resolves within 3 hours, but may recur with repeat dosing <a href="#FC2D8BA1-DA46-4179-95BE-CD62F2E70B5A">(5.4)</a>
</li>
<li>Evaluate patients with symptoms suggestive of mechanical <span class="product-label-link" type="condition" conceptid="4129389" conceptname="Gastrointestinal obstruction">gastrointestinal obstruction</span> prior to initiating treatment with Amitiza <a href="#FC2D8BA1-DA46-4179-95BE-CD62F2E70B2A">(5.5)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul>
<li>Most common adverse reactions (incidence &gt; 4%) in chronic idiopathic <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> are <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">abdominal distension</span>, and <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span> <a href="#AC7D2D64-A42E-4A60-B2CB-460F2BC8CCE9">(6.1)</a>
</li>
<li>Most common adverse reactions (incidence &gt; 4%) in <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">irritable bowel syndrome</span> with <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> are <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> <a href="#AC7D2D64-A42E-4A60-B2CB-460F2BC8CCE9">(6.1)</a>
</li>
</ul>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals North America, Inc., at 1-877-825-3327 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</span> </p>
</div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div><div></div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 10/2009</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Chronic Idiopathic <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></a></h2>
<h2><a href="#section-1.2" class="toc">1.2 <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">Irritable Bowel Syndrome</span> with <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	Chronic Idiopathic <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></a></h2>
<h2><a href="#section-2.2" class="toc">2.2	<span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">Irritable Bowel Syndrome</span> with <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Pregnancy</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">Bowel Obstruction</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Studies Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4  Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5  Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10  OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11  DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12  CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1  Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2  Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3  Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13  NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14  CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Chronic Idiopathic <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></a></h2>
<h2><a href="#section-13.2" class="toc">14.2 <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">Irritable Bowel Syndrome</span> with <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 Dosing Instructions</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="F28283A3-7F86-428B-AA02-520C9BB7F143"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="B417E142-21DE-4A69-B3F3-C3110156B6F7"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Chronic Idiopathic <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></h2>
<p class="First">Amitiza<span class="Sup">®</span> is indicated for the treatment of chronic idiopathic <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> in adults.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="B417E142-21DE-4A69-B3F3-C3110156B6F2"></a><a name="section-1.2"></a><p></p>
<h2>1.2 <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">Irritable Bowel Syndrome</span> with <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></h2>
<p class="First">
									Amitiza is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">irritable bowel syndrome</span> with <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (IBS-C) in women ≥ 18 years old.
								</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="CF896D38-8D33-4562-91C4-66E8927C4741"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">Amitiza should be taken twice daily orally with food and water. Physicians and patients should periodically assess the need for continued therapy.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="B417E142-21DE-4A69-B3F3-C3110156B6F3"></a><a name="section-2.1"></a><p></p>
<h2>2.1	Chronic Idiopathic <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></h2>
<p class="First">24 mcg twice daily orally with food and water.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="B417E142-21DE-4A69-B3F3-C3110156B6F4"></a><a name="section-2.2"></a><p></p>
<h2>2.2	<span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">Irritable Bowel Syndrome</span> with <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></h2>
<p class="First">
									8 mcg twice daily orally with food and water.
								</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="EB75313E-276E-4F49-AB3F-C919ED20A936"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Amitiza is available as an oval, gelatin capsule containing 8 mcg or 24 mcg of lubiprostone.</p>
<ul>
<li>8-mcg capsules are pink and are printed with "SPI" on one side</li>
<li>24-mcg capsules are orange and are printed with "SPI" on one side</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="C0725CD2-D44E-411A-B453-81F141BE2FC3"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Amitiza is contraindicated in patients with known or suspected mechanical <span class="product-label-link" type="condition" conceptid="4129389" conceptname="Gastrointestinal obstruction">gastrointestinal obstruction</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="FCA1E84E-82E2-4195-A4F3-2D8F2D10E291"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="B417E142-21DE-4A69-B3F3-C3110156B6F0"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Pregnancy</h2>
<p class="First">The safety of Amitiza in pregnancy has not been evaluated in humans. In guinea pigs, lubiprostone has been shown to have the potential to cause fetal loss. Amitiza should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Women who could become pregnant should have a <span class="product-label-link" type="condition" conceptid="4094448" conceptname="Pregnancy test negative">negative pregnancy test</span> prior to beginning therapy with Amitiza and should be capable of complying with effective contraceptive measures.  See <span class="Italics">Use in Specific Populations</span> (<a href="#E8698946-AFB8-492B-A57E-06DB903FCBC5">8.1</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="DB8DEB82-2604-4B6F-81CB-F668F46A382F"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></h2>
<p class="First">Patients taking Amitiza may experience <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>. If this occurs, concomitant administration of food with Amitiza may reduce symptoms of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>. See <span class="Italics">Adverse Reactions</span> (<a href="#AC7D2D64-A42E-4A60-B2CB-460F2BC8CCE9">6.1</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="D10AA7B0-552D-4F51-A02C-7E1437DE2B52"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></h2>
<p class="First">Amitiza should not be prescribed to patients that have severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. Patients should be aware of the possible occurrence of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> during treatment. Patients should be instructed to inform their physician if severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurs. See <span class="Italics">Adverse Reactions</span> (<a href="#AC7D2D64-A42E-4A60-B2CB-460F2BC8CCE9">6.1</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="FC2D8BA1-DA46-4179-95BE-CD62F2E70B5A"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></h2>
<p class="First">
									In clinical trials conducted to study Amitiza in treatment of chronic idiopathic <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> and IBS-C there were reports of <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>. This was reported at 2.5% of the treated chronic idiopathic <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> population and at 0.4% in the treated IBS-C population. Although not classified as serious adverse events, some patients discontinued treatment on study because of this event. There have been postmarketing reports of <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> when using Amitiza 24 mcg. Most have not been characterized as serious adverse events, but some patients have discontinued therapy because of <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>. These events have usually been described as a sensation of <span class="product-label-link" type="condition" conceptid="4034235" conceptname="Tight chest">chest tightness</span> and difficulty taking in a breath, and generally have an acute onset within 30–60 minutes after taking the first dose. They generally resolve within a few hours after taking the dose, but recurrence has been frequently reported with subsequent doses.
								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="FC2D8BA1-DA46-4179-95BE-CD62F2E70B2A"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">Bowel Obstruction</span></h2>
<p class="First">In patients with symptoms suggestive of mechanical <span class="product-label-link" type="condition" conceptid="4129389" conceptname="Gastrointestinal obstruction">gastrointestinal obstruction</span>, the treating physician should perform a thorough evaluation to confirm the absence of such an obstruction prior to initiating therapy with Amitiza.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="D7CDF8EB-6022-4186-8CC1-ED3A365698E4"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="AC7D2D64-A42E-4A60-B2CB-460F2BC8CCE9"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Studies Experience</h2>
<p class="First">Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.</p>
<p><span class="Bold">Chronic Idiopathic <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></span></p>
<p><span class="Italics">Adverse reactions in dose-finding, efficacy, and long-term clinical studies:</span> The data described below reflect exposure to Amitiza in 1175 patients with chronic idiopathic <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (29 at 24 mcg once daily, 1113 at 24 mcg twice daily, and 33 at 24 mcg three times daily) over 3- or 4-week, 6-month, and 12-month treatment periods; and from 316 patients receiving placebo over short-term exposure (≤ 4 weeks). The total population (N = 1491) had a mean age of 49.7 (range 19–86) years; was 87.1% female; 84.8% Caucasian, 8.5% African American, 5.0% Hispanic, 0.9% Asian; and 15.5% elderly (≥ 65 years of age). Table 1 presents data for the adverse reactions that occurred in at least 1% of patients who received Amitiza 24 mcg twice daily and that occurred more frequently with study drug than placebo. In addition, corresponding adverse reaction incidences in patients receiving Amitiza 24 mcg once daily is shown.</p>
<p></p>
<a name="a7523a7a-79c4-4b66-a496-a2824abae7dd"></a><table width="600">
<caption><span>Table 1: Percent of Patients with Adverse Reactions (Chronic Idiopathic <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>)</span></caption>
<col align="left" valign="middle" width="40%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<tfoot><tr class="First Last"><td align="left" colspan="4">
<p class="First"><span class="Sup">1</span>Includes only those events associated with treatment (possibly, probably, or definitely related, as assessed by the investigator).</p>
<p><span class="Sup">2</span>This term combines "<span class="product-label-link" type="condition" conceptid="197981" conceptname="Abdominal tenderness">abdominal tenderness</span>," "<span class="product-label-link" type="condition" conceptid="200215" conceptname="Abdominal rigidity">abdominal rigidity</span>," "<span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">gastrointestinal discomfort</span>," and "<span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>." </p>
</td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First">
<td align="left"><span class="Bold"><br>System/Adverse Reaction<span class="Sup">1</span></span></td>
<td align="center"><p class="First"><span class="Bold">Placebo<br><br><br></span><span class="Bold">N = 316<br></span><span class="Bold">%</span></p></td>
<td align="center"><p class="First"><span class="Bold">Amitiza<br></span><span class="Bold">24 mcg<br></span><span class="Bold">Once Daily</span><br><span class="Bold">N = 29<br></span><span class="Bold">%</span></p></td>
<td align="center"><p class="First"><span class="Bold">Amitiza<br></span><span class="Bold">24 mcg<br></span><span class="Bold">Twice Daily</span><br><span class="Bold">N = 1113<br></span><span class="Bold">%</span></p></td>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left"><p class="First">    <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td align="center">3</td>
<td align="center">17</td>
<td align="center">29</td>
</tr>
<tr>
<td align="left"><p class="First">    <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td align="center">&lt; 1</td>
<td align="center">7</td>
<td align="center">12</td>
</tr>
<tr>
<td align="left"><p class="First">    <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></p></td>
<td align="center">3</td>
<td align="center">3</td>
<td align="center">8</td>
</tr>
<tr>
<td align="left"><p class="First">    <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">Abdominal distension</span></p></td>
<td align="center">2</td>
<td align="center">-</td>
<td align="center">6</td>
</tr>
<tr>
<td align="left"><p class="First">    <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></p></td>
<td align="center">2</td>
<td align="center">3</td>
<td align="center">6</td>
</tr>
<tr>
<td align="left"><p class="First">    <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td align="center">-</td>
<td align="center">-</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left"><p class="First">    <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Loose stools</span></p></td>
<td align="center">-</td>
<td align="center">-</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left"><p class="First">    <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">Abdominal discomfort</span><span class="Sup">2</span></p></td>
<td align="center">&lt; 1</td>
<td align="center">3</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left"><p class="First">    <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></p></td>
<td align="center">&lt; 1</td>
<td align="center">-</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left"><p class="First">    <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></p></td>
<td align="center">&lt; 1</td>
<td align="center">-</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left"><p class="First">    <span class="product-label-link" type="condition" conceptid="4152197" conceptname="Stomach ache">Stomach discomfort</span></p></td>
<td align="center">&lt; 1</td>
<td align="center">-</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left"><p class="First">    <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td align="center">5</td>
<td align="center">3</td>
<td align="center">11</td>
</tr>
<tr>
<td align="left"><p class="First">    <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td align="center">&lt; 1</td>
<td align="center">3</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left"><span class="Bold">General disorders and site administration conditions</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left"><p class="First">    <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></p></td>
<td align="center">&lt; 1</td>
<td align="center">-</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left"><p class="First">    <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p></td>
<td align="center">&lt; 1</td>
<td align="center">-</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left"><p class="First">    <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">Chest discomfort</span>/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></p></td>
<td align="center">-</td>
<td align="center">3</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left"><span class="Bold">Respiratory, thoracic, and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span></span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr class="Last">
<td align="left"><p class="First">    <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></p></td>
<td align="center">-</td>
<td align="center">3</td>
<td align="center">2</td>
</tr>
</tbody>
</table>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>: </span>Approximately 29% of patients who received Amitiza 24 mcg twice daily experienced an adverse reaction of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>; 4% of patients had severe <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> while 9% of patients discontinued treatment due to <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>. The rate of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> associated with Amitiza (any dosage) was substantially lower among male (7%) and elderly patients (18%). Further analysis of the safety data revealed that long-term exposure to Amitiza does not appear to place patients at an elevated risk for experiencing <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>. The incidence of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> increased in a dose-dependent manner with the lowest overall incidence for <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> reported at the 24 mcg once daily dosage (17%). In open-labeled, long-term studies, patients were allowed to adjust the dosage of Amitiza down to 24 mcg once daily from 24 mcg twice daily if experiencing <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>. <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> decreased when Amitiza was administered with food. No patients in the clinical studies were hospitalized due to <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>:</span> Approximately 12% of patients who received Amitiza 24 mcg twice daily experienced an adverse reaction of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>; 2% of patients had severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> while 2% of patients discontinued treatment due to <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. </p>
<p><span class="Italics">Electrolytes:</span> No serious adverse reactions of <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> were reported in clinical studies, and no clinically significant changes were seen in serum electrolyte levels in patients receiving Amitiza.  </p>
<p><span class="Italics">Less common adverse reactions:</span> The following adverse reactions (assessed by investigator as probably or definitely related to treatment) occurred in less than 1% of patients receiving Amitiza 24 mcg twice daily in clinical studies, occurred in at least two patients, and occurred more frequently in patients receiving study drug than those receiving placebo: <span class="product-label-link" type="condition" conceptid="197675" conceptname="Incontinence of feces">fecal incontinence</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramp</span>, <span class="product-label-link" type="condition" conceptid="4216708" conceptname="Urgent desire for stool">defecation urgency</span>, <span class="product-label-link" type="condition" conceptid="4048265" conceptname="Increased frequency of defecation">frequent bowel movements</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>, pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4341223" conceptname="Bowel dysfunction">intestinal functional disorder</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">cold sweat</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>, <span class="product-label-link" type="condition" conceptid="4154927" conceptname="Joint swelling">joint swelling</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>. </p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">Irritable Bowel Syndrome</span> with <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></span></p>
<p><span class="Italics">Adverse reactions in dose-finding, efficacy, and long-term clinical studies:</span> The data described below reflect exposure to Amitiza 8 mcg twice daily in 1011 patients with IBS-C for up to 12 months and from 435 patients receiving placebo twice daily for up to 16 weeks. The total population (N = 1267) had a mean age of 46.5 (range 18–85) years; was 91.6% female; 77.5% Caucasian, 12.9% African American, 8.6% Hispanic, 0.4% Asian; and 8.0% elderly (≥ 65 years of age). Table 2 presents data for the adverse reactions that occurred in at least 1% of patients who received Amitiza 8 mcg twice daily and that occurred more frequently with study drug than placebo.</p>
<a name="a7523a7a-79c4-4b66-a496-a2824abae7de"></a><table width="600">
<caption><span>Table 2: Percent of Patients with Adverse Reactions (IBS-C Studies)</span></caption>
<col align="left" valign="middle" width="40%">
<col align="center" valign="middle" width="30%">
<col align="center" valign="middle" width="30%">
<tfoot><tr class="First Last"><td align="left" colspan="3"><p class="First"><span class="Sup">1</span>Includes only those events associated with treatment (possibly or probably related, as assessed by the investigator).</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First">
<td align="left"><span class="Bold"><br>System/Adverse Reaction<span class="Sup">1</span></span></td>
<td align="center"><p class="First"><span class="Bold">Placebo<br><br><br></span><span class="Bold">N = 435<br></span><span class="Bold">%</span></p></td>
<td align="center"><p class="First"><span class="Bold">Amitiza<br></span><span class="Bold">8 mcg<br></span><span class="Bold">Twice Daily</span><br><span class="Bold">N = 1011<br></span><span class="Bold">%</span></p></td>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left"><p class="First">    <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td align="center">4</td>
<td align="center">8</td>
</tr>
<tr>
<td align="left"><p class="First">    <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td align="center">4</td>
<td align="center">7</td>
</tr>
<tr>
<td align="left"><p class="First">    <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></p></td>
<td align="center">5</td>
<td align="center">5</td>
</tr>
<tr class="Last">
<td align="left"><p class="First">    <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">Abdominal distension</span></p></td>
<td align="center">2</td>
<td align="center">3</td>
</tr>
</tbody>
</table>
<p><span class="Italics">Less common adverse reactions:</span> The following adverse reactions (assessed by investigator as probably related to treatment) occurred in less than 1% of patients receiving Amitiza 8 mcg twice daily in clinical studies, occurred in at least two patients, and occurred more frequently in patients receiving study drug than those receiving placebo: <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, increased <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span>, increased <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux disease</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, increased weight, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="197675" conceptname="Incontinence of feces">fecal incontinence</span>, <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span>, hard feces, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">pollakiuria</span>.</p>
<p>One open-labeled, long-term clinical study was conducted in patients with IBS-C receiving Amitiza 8 mcg twice daily. This study comprised 476 intent-to-treat patients (mean age 47.5 [range 21–82] years; 93.5% female; 79.2% Caucasian, 11.6% African American, 8.6% Hispanic, 0.2% Asian; 7.8% ≥ 65 years of age) who were treated for an additional 36 weeks following an initial 12–16-week, double-blinded treatment period. The adverse reactions that were reported during this study were similar to those observed in the two double-blinded, controlled studies.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="DBE7679C-6C05-484D-AE63-B649689E1273"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of Amitiza 24 mcg for the treatment of chronic idiopathic <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p>Voluntary reports of adverse reactions occurring with the use of Amitiza include the following: <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, allergic-type reactions (including <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, and <span class="product-label-link" type="condition" conceptid="4194507" conceptname="Feeling of throat tightness">throat tightness</span>), <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, increased heart rate, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span> or <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="F8C044F9-86F2-4CFA-BE4C-1A6BEC63F7CB"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Based upon the results of <span class="Italics">in vitro</span> human microsome studies, there is low likelihood of drug–drug interactions. <span class="Italics">In vitro</span> studies using human liver microsomes indicate that cytochrome P450 isoenzymes are not involved in the metabolism of lubiprostone. Further <span class="Italics">in vitro</span> studies indicate microsomal carbonyl reductase may be involved in the extensive biotransformation of lubiprostone to the metabolite M3 (See <span class="Italics">Pharmacokinetics </span><a href="#E4B4A1F3-42E5-4E49-B6BD-8EFE2AC325CF">[12.3]</a>.). Additionally, <span class="Italics">in vitro</span> studies in human liver microsomes demonstrate that lubiprostone does not inhibit cytochrome P450 isoforms 3A4, 2D6, 1A2, 2A6, 2B6, 2C9, 2C19, or 2E1, and <span class="Italics">in vitro</span> studies of primary cultures of human hepatocytes show no induction of cytochrome P450 isoforms 1A2, 2B6, 2C9, and 3A4 by lubiprostone. No drug–drug interaction studies have been performed. Based on the available information, no protein binding–mediated drug interactions of clinical significance are anticipated.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="F3CA10FB-2A41-41F2-9349-3F620DA8AB7F"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="E8698946-AFB8-492B-A57E-06DB903FCBC5"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="ADB8D8C5-0AE2-418B-B217-8C27F720EABE"></a><a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Italics">Teratogenic effects:</span> Pregnancy Category C. [See <span class="Italics">Warnings and Precautions</span><a href="#B417E142-21DE-4A69-B3F3-C3110156B6F0">(5.1)</a>.]</p>
<p>Teratology studies with lubiprostone have been conducted in rats at oral doses up to 2000 mcg/kg/day (approximately 332 times the recommended human dose, based on body surface area), and in rabbits at oral doses of up to 100 mcg/kg/day (approximately 33 times the recommended human dose, based on body surface area). Lubiprostone was not teratogenic in rats or rabbits. In guinea pigs, lubiprostone caused fetal loss at repeated doses of 10 and 25 mcg/kg/day (approximately 2 and 6 times the highest recommended human dose, respectively, based on body surface area) administered on days 40 to 53 of gestation.</p>
<p>There are no adequate and well-controlled studies in pregnant women. However, during clinical testing of Amitiza, six women became pregnant. Per protocol, Amitiza was discontinued upon pregnancy detection. Four of the six women delivered healthy babies. The fifth woman was monitored for 1 month following discontinuation of study drug, at which time the pregnancy was progressing as expected; the patient was subsequently lost to follow-up. The sixth pregnancy was electively terminated.</p>
<p>Amitiza should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. If a woman is or becomes pregnant while taking the drug, the patient should be apprised of the potential hazard to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="EE02C7C5-6610-4BE2-B45A-65AB167B6C2D"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether lubiprostone is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from lubiprostone, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="F222C12B-EB6E-4E0C-B69F-1A49DA27A6F9"></a><a name="section-8.3"></a><p></p>
<h2>8.4  Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been studied.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ED822BFE-E577-4438-A2F3-6B7ABB1A2667"></a><a name="section-8.4"></a><p></p>
<h2>8.5  Geriatric Use</h2>
<p class="First"><span class="Bold">Chronic Idiopathic <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></span></p>
<p>The efficacy of Amitiza in the elderly (≥ 65 years of age) subpopulation was consistent with the efficacy in the overall study population. Of the total number of constipated patients treated in the dose-finding, efficacy, and long-term studies of Amitiza, 15.5% were ≥ 65 years of age, and 4.2% were ≥ 75 years of age. Elderly patients taking Amitiza (any dosage) experienced a lower incidence rate of associated <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> compared to the overall study population taking Amitiza (18% vs. 29%, respectively).</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">Irritable Bowel Syndrome</span> with <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></span></p>
<p>The safety profile of Amitiza in the elderly (≥ 65 years of age) subpopulation (8.0% were ≥ 65 years of age and 1.8% were ≥ 75 years of age) was consistent with the safety profile in the overall study population. Clinical studies of Amitiza did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently from younger patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="EBE4151E-8CD7-4881-B311-4DAEE4F6AE6E"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Amitiza has not been studied in patients who have <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="B9339FEC-86E5-4735-8DF5-C109727F648A"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Amitiza has not been studied in patients who have <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="D4561DFE-D2E2-4BBB-9216-A56272429B22"></a><a name="section-9"></a><p></p>
<h1>10  OVERDOSAGE</h1>
<p class="First">There have been two confirmed reports of overdosage with Amitiza. The first report involved a 3-year-old child who accidentally ingested 7 or 8 capsules of 24 mcg of Amitiza and fully recovered. The second report was a study patient who self-administered a total of 96 mcg of Amitiza per day for 8 days. The patient experienced no adverse reactions during this time. Additionally, in a Phase 1 cardiac repolarization study, 38 of 51 patients given a single oral dose of 144 mcg of Amitiza (6 times the highest recommended dose) experienced an adverse event that was at least possibly related to the study drug. Adverse reactions that occurred in at least 1% of these patients included the following: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (45%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (35%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (27%), <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (14%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (12%), <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (8%), <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>/hot flash (8%), <span class="product-label-link" type="condition" conceptid="4309379" conceptname="Retching">retching</span> (8%), <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> (4%), <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span> (4%), <span class="product-label-link" type="condition" conceptid="4152197" conceptname="Stomach ache">stomach discomfort</span> (4%), <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> (2%), <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span> (2%), <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">chest discomfort</span> (2%), <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> (2%), <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span> (2%), and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> (2%).</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="DBAB3EBD-1FCA-48D1-A4B1-C533A3C85934"></a><a name="section-10"></a><p></p>
<h1>11  DESCRIPTION</h1>
<p class="First">Amitiza (lubiprostone) is chemically designated as (–)-7-[(2<span class="Italics">R</span>,4a<span class="Italics">R</span>,5<span class="Italics">R</span>,7a<span class="Italics">R</span>)-2-(1,1-difluoropentyl)-2-hydroxy-6-oxooctahydrocyclopenta[<span class="Italics">b</span>]pyran-5-yl]heptanoic acid. The molecular formula of lubiprostone is C<span class="Sub">20</span>H<span class="Sub">32</span>F<span class="Sub">2</span>O<span class="Sub">5</span> with a molecular weight of 390.46 and a chemical structure as follows:</p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ca79dddc-3911-472b-bda7-a23351be09af&amp;name=amitiza-01.jpg"></p>
<p>Lubiprostone drug substance occurs as white, odorless crystals or crystalline powder, is very soluble in ether and ethanol, and is practically insoluble in hexane and water. Amitiza is available as an imprinted, oval, soft gelatin capsule in two strengths. Pink capsules contain 8 mcg of lubiprostone and the following inactive ingredients: medium-chain triglycerides, gelatin, sorbitol, ferric oxide, titanium dioxide, and purified water. Orange capsules contain 24 mcg of lubiprostone and the following inactive ingredients: medium-chain triglycerides, gelatin, sorbitol, FD&amp;C Red #40, D&amp;C Yellow #10, and purified water.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="D6D1AFAC-15E3-449B-BB8C-23864525376A"></a><a name="section-11"></a><p></p>
<h1>12  CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="F96817B1-5109-4ABC-BAD5-F3EAE9FB3CF1"></a><a name="section-11.1"></a><p></p>
<h2>12.1  Mechanism of Action</h2>
<p class="First">Lubiprostone is a locally acting chloride channel activator that enhances a chloride-rich intestinal fluid secretion without altering sodium and potassium concentrations in the serum. Lubiprostone acts by specifically activating ClC-2, which is a normal constituent of the apical membrane of the human intestine, in a protein kinase A–independent fashion. By increasing intestinal fluid secretion, lubiprostone increases motility in the intestine, thereby facilitating the passage of stool and alleviating symptoms associated with chronic idiopathic <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. Patch clamp cell studies in human cell lines have indicated that the majority of the beneficial biological activity of lubiprostone and its metabolites is observed only on the apical (luminal) portion of the gastrointestinal epithelium. Additionally, activation of ClC-2 by lubiprostone has been shown to stimulate recovery of mucosal barrier function via the restoration of tight junction protein complexes in <span class="Italics">ex vivo</span> studies of ischemic porcine intestine.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="F420C6BE-F9B0-45E5-B32C-A49BC9A154BC"></a><a name="section-11.2"></a><p></p>
<h2>12.2  Pharmacodynamics</h2>
<p class="First">Although the pharmacologic effects of lubiprostone in humans have not been fully evaluated, animal studies have shown that oral administration of lubiprostone increases chloride ion transport into the intestinal lumen, enhances fluid secretion into the bowels, and improves fecal transit.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="E4B4A1F3-42E5-4E49-B6BD-8EFE2AC325CF"></a><a name="section-11.3"></a><p></p>
<h2>12.3  Pharmacokinetics</h2>
<p class="First">Lubiprostone has low systemic availability following oral administration and concentrations of lubiprostone in plasma are below the level of quantitation (10 pg/mL). Therefore, standard pharmacokinetic parameters such as area under the curve (AUC), maximum concentration (C<span class="Sub">max</span>), and half-life (t<span class="Sub">½</span>) cannot be reliably calculated. However, the pharmacokinetic parameters of M3 (only measurable active metabolite of lubiprostone) have been characterized. Gender has no effect on the pharmacokinetics of M3 following the oral administration of lubiprostone.</p>
<p><span class="Bold Italics">Absorption</span></p>
<p>Concentrations of lubiprostone in plasma are below the level of quantitation (10 pg/mL) because lubiprostone has a low systemic availability following oral administration. Peak plasma levels of M3, after a single oral dose with 24 mcg of lubiprostone, occurred at approximately 1.10 hours. The C<span class="Sub">max</span> was 41.5 pg/mL and the mean AUC<span class="Sub">0–t</span> was 57.1 pg∙hr/mL. The AUC<span class="Sub">0–t</span> of M3 increases dose proportionally after single 24-mcg and 144-mcg doses of lubiprostone.</p>
<p><span class="Bold Italics">Distribution</span></p>
<p><span class="Italics">In vitro</span> protein binding studies indicate lubiprostone is approximately 94% bound to human plasma proteins. Studies in rats given radiolabeled lubiprostone indicate minimal distribution beyond the gastrointestinal tissues. Concentrations of radiolabeled lubiprostone at 48 hours post-administration were minimal in all tissues of the rats.</p>
<p><span class="Bold Italics">Metabolism</span></p>
<p>The results of both human and animal studies indicate that lubiprostone is rapidly and extensively metabolized by 15-position reduction, α-chain β-oxidation, and ω-chain ω-oxidation. These biotransformations are not mediated by the hepatic cytochrome P450 system but rather appear to be mediated by the ubiquitously expressed carbonyl reductase. M3, a metabolite of lubiprostone found in both humans and animals, is formed by the reduction of the carbonyl group at the 15-hydroxy moiety that consists of both α-hydroxy and β-hydroxy epimers. M3 makes up less than 10% of the dose of radiolabeled lubiprostone. Animal studies have shown that metabolism of lubiprostone rapidly occurs within the stomach and jejunum, most likely in the absence of any systemic absorption. This is presumed to be the case in humans as well.</p>
<p><span class="Bold Italics">Elimination</span></p>
<p>Lubiprostone could not be detected in plasma; however, M3 has a t<span class="Sub">½</span> ranging from 0.9 to 1.4 hours. After a single oral dose of 72 mcg of <span class="Sup">3</span>H-labeled lubiprostone, 60% of total administered radioactivity was recovered in the urine within 24 hours and 30% of total administered radioactivity was recovered in the feces by 168 hours. Lubiprostone and M3 are only detected in trace amounts in human feces.</p>
<p><span class="Bold Italics">Food Effect</span></p>
<p>A study was conducted with a single 72-mcg dose of <span class="Sup">3</span>H-labeled lubiprostone to evaluate the potential of a food effect on lubiprostone absorption, metabolism, and excretion. Pharmacokinetic parameters of total radioactivity demonstrated that C<span class="Sub">max</span> decreased by 55% while AUC<span class="Sub">0–∞</span> was unchanged when lubiprostone was administered with a high-fat meal. The clinical relevance of the effect of food on the pharmacokinetics of lubiprostone is not clear. However, lubiprostone was administered with food and water in a majority of clinical trials.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="D08EBE33-A9C2-4FAC-B992-03B565EB7EC4"></a><a name="section-12"></a><p></p>
<h1>13  NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="BC925BB1-901C-4471-A7D3-B724671D66D8"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Bold">Carcinogenesis</span></p>
<p>Two 2-year oral (gavage) carcinogenicity studies (one in Crl:B6C3F1 mice and one in Sprague-Dawley rats) were conducted with lubiprostone. In the 2-year carcinogenicity study in mice, lubiprostone doses of 25, 75, 200, and 500 mcg/kg/day (approximately 2, 6, 17, and 42 times the highest recommended human dose, respectively, based on body surface area) were used. In the 2-year rat carcinogenicity study, lubiprostone doses of 20, 100, and 400 mcg/kg/day (approximately 3, 17, and 68 times the highest recommended human dose, respectively, based on body surface area) were used. In the mouse carcinogenicity study, there was no significant increase in any tumor incidences. There was a significant increase in the incidence of interstitial cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenoma</span> of the testes in male rats at the 400 mcg/kg/day dose. In female rats, treatment with lubiprostone produced <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatocellular adenoma</span> at the 400 mcg/kg/day dose.</p>
<p><span class="Bold">Mutagenesis</span></p>
<p>Lubiprostone was not genotoxic in the <span class="Italics">in vitro</span> Ames reverse mutation assay, the <span class="Italics">in vitro</span> mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> (L5178Y TK<span class="Sup"> +/–</span>) forward mutation assay, the <span class="Italics">in vitro</span> Chinese hamster lung (CHL/IU) chromosomal aberration assay, and the <span class="Italics">in vivo</span> mouse bone marrow micronucleus assay.</p>
<p><span class="Bold">Impairment of Fertility</span></p>
<p>Lubiprostone, at oral doses of up to 1000 mcg/kg/day, had no effect on the fertility and reproductive function of male and female rats. However, the number of implantation sites and live embryos were significantly reduced in rats at the 1000 mcg/kg/day dose as compared to control. The number of dead or resorbed embryos in the 1000 mcg/kg/day group was higher compared to the control group, but was not statistically significant. The 1000 mcg/kg/day dose in rats is approximately 166 times the highest recommended human dose of 48 mcg/day, based on body surface area.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="C696FE94-22FC-4EE3-822C-57BDB24CB6E3"></a><a name="section-13"></a><p></p>
<h1>14  CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="C31E577F-41B9-4947-9D91-FBEB13A62432"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Chronic Idiopathic <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></h2>
<p class="First"><span class="Bold">Dose-finding Study</span></p>
<p>A dose-finding, double-blinded, parallel-group, placebo-controlled, Phase 2 study was conducted in patients with chronic idiopathic <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. Following a 2-week baseline/washout period, patients (N = 127) were randomized to receive placebo (n = 33), Amitiza 24 mcg/day (24 mcg once daily; n = 29), Amitiza 48 mcg/day (24 mcg twice daily; n = 32), or Amitiza 72 mcg/day (24 mcg three times daily; n = 33) for 3 weeks. Patients were chosen for participation based on their need for relief of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, which was defined as less than 3 spontaneous bowel movements (SBMs) per week. The primary efficacy variable was the daily average number of SBMs.</p>
<p>The study demonstrated that all patients who took Amitiza experienced a noticeable improvement in clinical response. Based on the efficacy analysis, there was no statistically significant improvement in the clinical response beyond a total daily dose of 24 mcg during treatment weeks 2 and 3 (Figure 1).</p>
<p><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ca79dddc-3911-472b-bda7-a23351be09af&amp;name=amitiza-02.jpg"></p>
<p><span class="Bold">Figure 1: Weekly Mean (± Standard Error) Spontaneous Bowel Movements (Dose-finding Study)</span></p>
<p><span class="Bold">Efficacy Studies</span></p>
<p>Two double-blinded, placebo-controlled studies of identical design were conducted in patients with chronic idiopathic <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. Chronic idiopathic <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> was defined as, on average, less than 3 SBMs per week along with one or more of the following symptoms of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> for at least 6 months prior to randomization: 1) very hard stools for at least a quarter of all bowel movements; 2) sensation of incomplete evacuation following at least a quarter of all bowel movements; and 3) straining with defecation at least a quarter of the time.</p>
<p>Following a 2-week baseline/washout period, a total of 479 patients (mean age 47.2 [range 20–81] years; 88.9% female; 80.8% Caucasian, 9.6% African American, 7.3% Hispanic, 1.5% Asian; 10.9% ≥ 65 years of age) were randomized and received Amitiza 24 mcg twice daily (48 mcg/day) or placebo twice daily for 4 weeks. The primary endpoint of the studies was SBM frequency. The studies demonstrated that patients treated with Amitiza had a higher frequency of SBMs during Week 1 than the placebo patients. In both studies, results similar to those in Week 1 were also observed in Weeks 2, 3, and 4 of therapy (Table 3).</p>
<a name="efa1f4c9-1e7b-40cf-bc0d-728ad31ed5d7"></a><table width="700">
<caption><span>Table 3: Spontaneous Bowel Movement Frequency Rates<span class="Sup">1</span> (Efficacy Studies)</span></caption>
<col align="left" valign="middle" width="12%">
<col align="center" valign="middle" width="11%">
<col align="center" valign="middle" width="11%">
<col align="center" valign="middle" width="11%">
<col align="center" valign="middle" width="11%">
<col align="center" valign="middle" width="11%">
<col align="center" valign="middle" width="11%">
<col align="center" valign="middle" width="11%">
<col align="center" valign="middle" width="11%">
<tfoot><tr class="First Last"><td align="left" colspan="9"><p class="First"><span class="Sup">1</span>Frequency rates are calculated as 7 times (number of SBMs) / (number of days observed for that week).</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First">
<td align="left"><span class="Bold"><br><br>Trial</span></td>
<td align="center"><span class="Bold"><br><br>Study Arm</span></td>
<td align="center"><p class="First"><span class="Bold"><br>Baseline<br></span><span class="Italics">Mean ± SD<br></span><span class="Italics">Median</span></p></td>
<td align="center"><p class="First"><span class="Bold"><br>Week 1<br></span><span class="Italics">Mean ± SD<br></span><span class="Italics">Median</span></p></td>
<td align="center"><p class="First"><span class="Bold"><br>Week 2<br></span><span class="Italics">Mean ± SD<br></span><span class="Italics">Median</span></p></td>
<td align="center"><p class="First"><span class="Bold"><br>Week 3<br></span><span class="Italics">Mean ± SD<br></span><span class="Italics">Median</span></p></td>
<td align="center"><p class="First"><span class="Bold"><br>Week 4<br></span><span class="Italics">Mean ± SD<br></span><span class="Italics">Median</span></p></td>
<td align="center"><p class="First"><span class="Bold">Week 1 Change<br>from Baseline<br></span><span class="Italics">Mean ± SD<br></span><span class="Italics">Median</span></p></td>
<td align="center"><p class="First"><span class="Bold">Week 4 Change<br>from Baseline <br></span><span class="Italics">Mean ± SD<br></span><span class="Italics">Median</span></p></td>
</tr>
<tr>
<td align="left"></td>
<td align="center"><span class="Bold">Placebo</span></td>
<td align="center"><p class="First">1.6 ± 1.3<br>1.5</p></td>
<td align="center"><p class="First">3.5 ± 2.3<br>3.0</p></td>
<td align="center"><p class="First">3.2 ± 2.5<br>3.0</p></td>
<td align="center"><p class="First">2.8 ± 2.2<br>2.0</p></td>
<td align="center"><p class="First">2.9 ± 2.4<br>2.3</p></td>
<td align="center"><p class="First">1.9 ± 2.2<br>1.5</p></td>
<td align="center"><p class="First">1.3 ± 2.5<br>1.0</p></td>
</tr>
<tr><td align="left" colspan="9"><span class="Bold">Study 1</span></td></tr>
<tr class="Botrule">
<td align="left"></td>
<td align="center"><span class="Bold">Amitiza<br>24 mcg<br>Twice Daily</span></td>
<td align="center"><p class="First">1.4 ± 0.8<br>1.5</p></td>
<td align="center"><p class="First">5.7 ± 4.4<br>5.0</p></td>
<td align="center"><p class="First">5.1 ± 4.1<br>4.0</p></td>
<td align="center"><p class="First">5.3 ± 4.9<br>5.0</p></td>
<td align="center"><p class="First">5.3 ± 4.7<br>4.0</p></td>
<td align="center"><p class="First">4.3 ± 4.3<br>3.5</p></td>
<td align="center"><p class="First">3.9 ± 4.6<br>3.0</p></td>
</tr>
<tr>
<td align="left"></td>
<td align="center"><span class="Bold">Placebo</span></td>
<td align="center"><p class="First">1.5 ± 0.8<br>1.5</p></td>
<td align="center"><p class="First">4.0 ± 2.7<br>3.5</p></td>
<td align="center"><p class="First">3.6 ± 2.7<br>3.0</p></td>
<td align="center"><p class="First">3.4 ± 2.8<br>3.0</p></td>
<td align="center"><p class="First">3.5 ± 2.9<br>3.0</p></td>
<td align="center"><p class="First">2.5 ± 2.6<br>1.5</p></td>
<td align="center"><p class="First">1.9 ± 2.7<br>1.5</p></td>
</tr>
<tr>
<td align="left"><span class="Bold">Study 2</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr class="Last">
<td align="left"></td>
<td align="center"><span class="Bold">Amitiza<br>24 mcg<br>Twice Daily</span></td>
<td align="center"><p class="First">1.3 ± 0.9<br>1.5</p></td>
<td align="center"><p class="First">5.9 ± 4.0<br>5.0</p></td>
<td align="center"><p class="First">5.0 ± 4.2<br>4.0</p></td>
<td align="center"><p class="First">5.6 ± 4.6<br>5.0</p></td>
<td align="center"><p class="First">5.4 ± 4.8<br>4.3</p></td>
<td align="center"><p class="First">4.6 ± 4.1<br>3.8</p></td>
<td align="center"><p class="First">4.1 ± 4.8<br>3.0</p></td>
</tr>
</tbody>
</table>
<p>In both studies, Amitiza demonstrated increases in the percentage of patients who experienced SBMs within the first 24 hours after administration when compared to placebo (56.7% vs. 36.9% in Study 1 and 62.9% vs. 31.9% in Study 2, respectively). Similarly, the time to first SBM was shorter for patients receiving Amitiza than for those receiving placebo.</p>
<p>Signs and symptoms related to <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, including <span class="product-label-link" type="condition" conceptid="4023572" conceptname="Abdominal bloating">abdominal bloating</span>, <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>, stool consistency, and straining, as well as <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> severity ratings, were also improved with Amitiza versus placebo. The results were consistent in subpopulation analyses for gender, race, and elderly patients (≥ 65 years of age).</p>
<p>Following 4 weeks of treatment with Amitiza 24 mcg twice daily, withdrawal of Amitiza did not result in a rebound effect.</p>
<p><span class="Bold">Long-term Studies</span></p>
<p>Three open-labeled, long-term clinical safety and efficacy studies were conducted in patients with chronic idiopathic <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> receiving Amitiza 24 mcg twice daily. These studies comprised 871 patients (mean age 51.0 [range 19–86] years; 86.1% female; 86.9% Caucasian, 7.3% African American, 4.5% Hispanic, 0.7% Asian; 18.4% ≥ 65 years of age) who were treated for 6–12 months (24–48 weeks). Patients provided regular assessments of <span class="product-label-link" type="condition" conceptid="4023572" conceptname="Abdominal bloating">abdominal bloating</span>, <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>, and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> severity. These studies demonstrated that Amitiza decreased <span class="product-label-link" type="condition" conceptid="4023572" conceptname="Abdominal bloating">abdominal bloating</span>, <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>, and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> severity over the 6–12-month treatment periods.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="B9B0ADDA-48BD-4054-B2CF-74D684408E32"></a><a name="section-13.2"></a><p></p>
<h2>14.2 <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">Irritable Bowel Syndrome</span> with <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></h2>
<p class="First"><span class="Bold">Efficacy Studies</span></p>
<p>Two double-blinded, placebo-controlled studies of similar design were conducted in patients with IBS-C. IBS was defined as <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> occurring over at least 6 months with two or more of the following: 1) relieved with defecation; 2) onset associated with a change in stool frequency; and 3) onset associated with a change in stool form. Patients were sub-typed as having IBS-C if they also experienced two of three of the following: 1) &lt; 3 spontaneous bowel movements per week, 2) &gt; 25% hard stools, and 3) &gt; 25% spontaneous bowel movements associated with straining.</p>
<p>Following a 4-week baseline/washout period, a total of 1154 patients (mean age 46.6 [range 18–85] years; 91.6% female; 77.4% Caucasian, 13.2% African American, 8.5% Hispanic, 0.4% Asian; 8.3% ≥ 65 years of age) were randomized and received Amitiza 8 mcg twice daily (16 mcg/day) or placebo twice daily for 12 weeks. The primary efficacy endpoint was assessed weekly utilizing the patient's response to a global symptom relief question based on a 7-point, balanced scale ("significantly worse" to "significantly relieved"): "How would you rate your relief of IBS symptoms (<span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, bowel habits, and other IBS symptoms) over the past week compared to how you felt before you entered the study?"</p>
<p>The primary efficacy analysis was a comparison of the proportion of "overall responders" in each arm. A patient was considered an "overall responder" if the criteria for being designated a "monthly responder" were met in at least 2 of the 3 months on study. A "monthly responder" was defined as a patient who had reported "significantly relieved" for at least 2 weeks of the month or at least "moderately relieved" in all 4 weeks of that month. During each monthly evaluation period, patients reporting "moderately worse" or "significantly worse" relief, an increase in rescue medication use, or those who discontinued due to lack of efficacy, were deemed non-responders.</p>
<p>The percentage of patients in Study 1 qualifying as an "overall responder" was 13.8% in the group receiving Amitiza 8 mcg twice daily compared to 7.8% of patients receiving placebo twice daily. In Study 2, 12.1% of patients in the Amitiza 8 mcg group were "overall responders" versus 5.7% of patients in the placebo group. In both studies, the treatment differences between the placebo and Amitiza groups were statistically significant.</p>
<p><span class="Italics">Results in men:</span> The two randomized, placebo-controlled, double-blinded studies comprised 97 (8.4%) male patients, which is insufficient to determine whether men with IBS-C respond differently to Amitiza from women.</p>
<p>Study 1 also assessed the rebound effect from the withdrawal of Amitiza. Following 12 weeks of treatment with Amitiza 8 mcg twice daily, withdrawal of Amitiza did not result in a rebound effect.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="F10482E4-2DFD-4573-AD53-B5CBF9A1A39E"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Amitiza is available as an oval, soft gelatin capsule containing 8 mcg or 24 mcg of lubiprostone with "SPI" printed on one side. Amitiza is available as follows:</p>
<br><p>8-mcg pink capsule</p>
<ul><li>Bottles of 60 (NDC 64764-080-60)</li></ul>
<p>24-mcg orange capsule</p>
<ul>
<li>Bottles of 60 (NDC 64764-240-60)</li>
<li>Bottles of 100 (NDC 64764-240-10)</li>
</ul>
<p>Store at 25°C (77°F); excursions permitted to 15°–30°C (59°–86°F).</p>
<p>PROTECT FROM EXTREME TEMPERATURES.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="B2D1E9A4-2450-46E0-A660-B8372972D447"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="B08EC720-A507-4EC1-A514-3B4A7254259C"></a><a name="section-15.1"></a><p></p>
<h2>17.1 Dosing Instructions</h2>
<p class="First">Amitiza should be taken twice daily with food and water to reduce potential symptoms of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>. The capsule should be taken once in the morning and once in the evening daily as prescribed. The capsule should be swallowed whole and should not be broken apart or chewed. Physicians and patients should periodically assess the need for continued therapy.</p>
<p>Patients on treatment who experience severe <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> should inform their physician. Patients taking Amitiza may experience <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> within an hour of the first dose. This symptom generally resolves within 3 hours, but may recur with repeat dosing.</p>
<p><span class="Bold">Chronic Idiopathic <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></span></p>
<p>Patients should take a single 24 mcg capsule of Amitiza twice daily with food and water.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">Irritable Bowel Syndrome</span> with <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></span></p>
<p>Patients should take a single 8 mcg capsule of Amitiza twice daily with food and water.</p>
<p><span class="Bold">Marketed by:</span></p>
<p>Sucampo Pharma Americas, Inc.<br> Bethesda, MD 20814</p>
<p>and</p>
<p>Takeda Pharmaceuticals America, Inc.<br> Deerfield, IL 60015</p>
<p>Amitiza<span class="Sup">®</span> is a registered trademark of Sucampo Pharmaceuticals, Inc.</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<p class="First"><img alt="AMITIZA 8MCG LABEL IMAGE" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ca79dddc-3911-472b-bda7-a23351be09af&amp;name=AMITIZA%208MCG%20LABEL.jpg">     AMITIZA 8MCG LABEL IMAGE</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AMITIZA 		
					</strong><br><span class="contentTableReg">lubiprostone capsule, gelatin coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:16590-622(NDC:64764-080)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LUBIPROSTONE</strong> (LUBIPROSTONE) </td>
<td class="formItem">LUBIPROSTONE</td>
<td class="formItem">8 ug</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MEDIUM-CHAIN TRIGLYCERIDES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SORBITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">pink</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (OVAL, SOFT GELATIN CAPSULE) </td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">SPI</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:16590-622-30</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:16590-622-60</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:16590-622-90</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021908</td>
<td class="formItem">01/31/2006</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>STAT RX USA LLC
							(786036330)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">STAT RX USA LLC</td>
<td class="formItem"></td>
<td class="formItem">786036330</td>
<td class="formItem">repack, relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>9fc144cb-399d-4dd0-8e98-76196fb88e44</div>
<div>Set id: ca79dddc-3911-472b-bda7-a23351be09af</div>
<div>Version: 1</div>
<div>Effective Time: 20100721</div>
</div>
</div> <div class="DistributorName">STAT RX USA LLC</div></p>
</body></html>
